<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927898</url>
  </required_header>
  <id_info>
    <org_study_id>18-223/1781</org_study_id>
    <nct_id>NCT03927898</nct_id>
  </id_info>
  <brief_title>Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis</brief_title>
  <official_title>Phase II Study of Toripalimab (JS001) Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic colorectal cancer is one of the common malignant tumors and the overall prognosis
      is poor. The introduction of immune-checkpoint inhibition (ICI) has led to a paradigm shift
      in the treatment of patients with metastatic cancer. Stereotactic body radiation therapy
      (SBRT) delivers a large dose of radiation to the tumor target with high precision while
      sparing irradiation of the surrounding normal tissues. It is suggested that SBRT could be the
      most appropriate radiotherapy modality to be combined with immunotherapy since it induces the
      expression of a series of cytokines and new tumour-associated antigens (TAAs) and is more
      likely to cause intense immune response and exert an abscopal effect than conventional
      radiotherapy.

      Thus, this study is to explore the use of SBRT in combination with ICI in colorectal cancer
      patients with oligometastasis, in order to get better local and systemic tumor control and
      improve progress-free survival (PFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to recruit patients with mCRC, who have received first-line systemic
      therapy for more than 3 months and achieved PR/SD. Than all the patients will receive SBRT
      followed by ICI therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All enrolled patients will receive Toripalimab following stereotactic body radiotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year Progression-Free-Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>1 year PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3-5 acute adverse events</measure>
    <time_frame>6 months since last treatment of Toripalimab</time_frame>
    <description>Grade 3-5 acute adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>At the end of 4 cycles of Toripalimab (each cycle is 21 days)</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year local control rate</measure>
    <time_frame>2 year</time_frame>
    <description>2 year local control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>2 year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell receptor repertoire and T cell clones in peripheral blood</measure>
    <time_frame>At the end of 6 cycles of Toripalimab (each cycle is 21 days)</time_frame>
    <description>Change of T cell receptor repertoire and T cell clones in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of PD-1, ki-67 on T cell</measure>
    <time_frame>At the end of 6 cycles of Toripalimab (each cycle is 21 days)</time_frame>
    <description>Change of expression of PD-1, ki-67 on T cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of PD-L1 on Exosomes in peripheral blood</measure>
    <time_frame>At the end of 6 cycles of Toripalimab (each cycle is 21 days)</time_frame>
    <description>Change of expression of PD-L1 on Exosomes in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of PD-L1 on circulation tumor cell</measure>
    <time_frame>At the end of 6 cycles of Toripalimab (each cycle is 21 days)</time_frame>
    <description>Change of expression of PD-L1 on circulation tumor cell</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT+Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received SBRT (BED&gt;80Gy) to oligometastatic lesions and then receive Toripalimab (240mg)/q3w till progression of disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT</description>
    <arm_group_label>SBRT+Toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy</intervention_name>
    <description>Participants receive SBRT (BED&gt;80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w</description>
    <arm_group_label>SBRT+Toripalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age：18-75 years old , Eastern Cooperative Oncology Group (ECOG) performance status of
             0-1

          2. Histologically confirmed CRC , metastatic CRC , subjects have received first-line
             systemic therapy for more than 3 months and achieved PR/SD, the interval between last
             systemic therapy and SBRT is≥4 weeks

          3. The primary site has been controlled by surgery

          4. Patient has at least 1 lesion of measurable metastatic disease by Response Evaluation
             Criteria in Solid Tumors (RECIST) version 1.1 and iRECIST , and who can achieve the
             status of non evidence of disease after local ablative therapy. The number of lesion
             is ≤ 5, the maximum diameter of the lesion is ≤5cm ,

          5. All metastatic lesions are amenable to SBRT with BED≥80Gy in 3 to 5 fractions;

          6. Have a life expectancy of at least 6 months

          7. Adequate organ function, as defined by the following:

             Hemoglobin ≥ 100 g/L; White blood cell count (WBC) ≥3.5×109/L , Absolute neutrophil
             count (ANC) ≥ 1.5×109/L; Platelets ≥75×109/L; Serum creatinine ≤ 1.0 x institutional
             upper limit of normal (ULN) ; Blood Urea Nitrogen(BUN) ≤ 1.0 x institutional (ULN)
             Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 x
             institutional ULN ALkaline Phosphatase (ALP) ≤ 1.5 x institutional ULN Serum total
             bilirubin (TBIL) ≤1.5 x institutional ULN Urine protein is negative , Coagulation
             function is normal

          8. patients and his/her mate must agree to follow instructions for method(s) of
             contraception for the duration of treatment with study drug；

          9. Patient must have the ability to understand and the willingness to sign a written
             informed consent document.

        Exclusion Criteria:

          1. Serious autoimmune disease at the discretion of the treating attending，subjects with
             leukodermia，allergic asthma syndrome will not be excluded from the study.

          2. Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          3. Has evidence of interstitial lung disease or active, non-infectious pneumonitis
             requiring systemic steroids.

          4. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to study Day 1 of the
             trial treatment.

          5. Has a known additional malignancy，subjects with basal cell carcinoma (BCC)， squamous
             cell carcinoma of skin and carcinoma in situ of cervix will not be excluded from the
             study.

          6. Has received a vaccine within 30 days prior to study Day 1 of the trial treatment or
             will receive a vaccine after the trial treatment; active HBV，HCV infection

          7. Has received systemic therapy within 4 weeks prior to study Day 1 of the trial
             treatment or who has not recovered from adverse events due to a previously
             administered agent.

             Note: Subjects with ≤ Grade 2 neuropathy or myelosuppression are an exception to this
             criterion and may qualify for the study.

          8. Any underlying medical or psychiatric condition: partial endocrine organ deficiencies
             , serious cardiac，pulmonary，renal disease，active infectious disease.

          9. Active diverticulitis, intra-abdominal abscess, Gastrointestinal (GI) obstruction,
             abdominal carcinomatosis , frequent diarrhea or other known risk factors for bowel
             perforation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jing Jin, M.D</last_name>
    <phone>+86-1087787568</phone>
    <email>jingjin1025@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianyang Wang, M.D.</last_name>
    <phone>+86-1087788122</phone>
    <email>pkucell@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyang Liu, MD</last_name>
      <email>liuwenyang26@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyang Wang, MD</last_name>
      <phone>+86-13810095191</phone>
      <email>pkucell@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Jin, MD</last_name>
      <phone>+86-10-87788122</phone>
      <email>jingjin1025@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Jin, MD</last_name>
      <phone>+8613601365130</phone>
      <email>jingjin1025@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.</citation>
    <PMID>27380959</PMID>
  </reference>
  <reference>
    <citation>Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A; SBRT for CRC liver metastases. Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiother Oncol. 2018 Dec;129(3):427-434. doi: 10.1016/j.radonc.2018.06.035. Epub 2018 Jul 9.</citation>
    <PMID>29997034</PMID>
  </reference>
  <reference>
    <citation>Joo JH, Park JH, Kim JC, Yu CS, Lim SB, Park IJ, Kim TW, Hong YS, Kim KP, Yoon SM, Park J, Kim JH. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):876-883. doi: 10.1016/j.ijrobp.2017.07.030. Epub 2017 Jul 31.</citation>
    <PMID>29063852</PMID>
  </reference>
  <reference>
    <citation>Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.</citation>
    <PMID>29437535</PMID>
  </reference>
  <reference>
    <citation>Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009 Jul 16;114(3):589-95. doi: 10.1182/blood-2009-02-206870. Epub 2009 Apr 6.</citation>
    <PMID>19349616</PMID>
  </reference>
  <reference>
    <citation>Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20.</citation>
    <PMID>27649551</PMID>
  </reference>
  <reference>
    <citation>Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR; CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.</citation>
    <PMID>24831977</PMID>
  </reference>
  <reference>
    <citation>Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.</citation>
    <PMID>28397821</PMID>
  </reference>
  <reference>
    <citation>Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018 Aug;560(7718):382-386. doi: 10.1038/s41586-018-0392-8. Epub 2018 Aug 8.</citation>
    <PMID>30089911</PMID>
  </reference>
  <reference>
    <citation>Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.</citation>
    <PMID>28271869</PMID>
  </reference>
  <reference>
    <citation>Hanna GG, Murray L, Patel R, Jain S, Aitken KL, Franks KN, van As N, Tree A, Hatfield P, Harrow S, McDonald F, Ahmed M, Saran FH, Webster GJ, Khoo V, Landau D, Eaton DJ, Hawkins MA. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14. doi: 10.1016/j.clon.2017.09.007. Epub 2017 Oct 13.</citation>
    <PMID>29033164</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>Professor of Dept.of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

